Co-Diagnostics, Inc. Launches Vector Control Mosquito Test for EEE Virus
December 10 2019 - 6:30AM
Business Wire
Vector Smart™ NAM-e multiplex PCR test to
provide proactive defense against mosquito populations carrying the
deadly eastern equine encephalitis virus
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of diagnostic tests, announced today the launch of
their Vector Smart™ NAM-e (North American Mosquito-East) multiplex
test, which detects the eastern equine encephalitis (EEE) virus
among mosquito populations, along with West Nile virus (WNV) and
St. Louis encephalitis (SLE).
EEE is a mosquito-borne disease that kills roughly one-third of
those infected and typically leaves survivors with “mild to severe
brain damage” according to the CDC. 2019 brought an unexpected
surge in cases of EEE in the US, more than 5 times the average, and
the 36 confirmed cases across 8 states resulted in 14 deaths.
Mosquito populations are tested, monitored, and controlled by
over 1,000 MADs (mosquito abatement districts, publicly funded
departments at the city, county, and state level) in North America.
The Company has been presenting its mosquito diagnostic products to
MADs at vector control conferences across the country this year.
Revenue from the Company’s mosquito abatement vertical began
earlier in 2019, and is expected to significantly increase as
demand grows for the NAM-e and other tests to help provide a
first-line of defense against the spread of certain mosquito-borne
illnesses.
Like the other tests in the Company’s Vector Smart line of PCR
products, the NAM-e test was validated using extractions from
mosquito samples rather than humans and includes an extraction
control specifically for mosquitoes, to reduce the possibility of a
false negative result due to an improper extraction. The Company’s
NAM-e test is similar to its Vector Smart NAM-w multiplex assay for
WNV, SLE and western equine encephalitis (WEE), but identifies EEE
instead of WEE.
“Since the launch of our NAM-w test earlier this year,
developing a diagnostic tool to identify EEE has been far and away
the most frequent request from this industry,” remarked Dwight
Egan, CEO of Co-Diagnostics. “We were pleased to be able to quickly
leverage our propriety platform and design process, and to deliver
such a high-quality diagnostic to meet this demand. Co-Diagnostics
is an active participant in preventing the spread of so many
dangerous diseases, particularly as our Vector Smart tests are some
of the only products of their kind in this market.”
Follow this link to hear a discussion by Mr. Egan about the
importance and impact of the Company’s new test and other recent
Company events: https://youtu.be/uQTxPsArVkk
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding the (i) use of funding
proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191210005364/en/
Andrew Benson Head of Investor Relations +1 801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024